Isis Pharma (ISIS) Cash Flow Statement

Click line-items for a historical chart and %

Net cash used in operating activities
Purchases of short-term investments	-234.49M
Proceeds from the sale of short-term investments	277.97M
Purchases of property, plant and equipment	-4.31M
Proceeds from land sold to BioMed
Reduction of cash due to deconsolidation of Regulus Therapeutics Inc. upon adoption of a new accounting standard
Acquisition of licenses and other assets
Purchases of strategic investments
Net cash (used in) provided by investing activities
Proceeds from issuance of equity	7.25M
Proceeds from equipment financing arrangement
Principal payments on debt obligations	-5.43M
Net cash (used in) provided by financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period	128.8M
Cash and cash equivalents at end of period	84.28M
Interest paid
Income taxes paid
Amounts accrued for capital and patent expenditures
Capitalized costs and financing liability associated with leased facility

Entities mentioned with ISIS

View All Entities